Business Wire

MA-HOLOGIC

Share
Hologic Expands its Omni® Hysteroscopy Offering in Europe

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has launched its expanded Omni® suite, a comprehensive gynecological surgical offering designed to optimize diagnostic and operative hysteroscopy, in Europe, Africa and the Middle East (EMEA). The offering now includes a versatile Omni 30° hysteroscope, the Omni Lok cervical seal and the Omni 5 French seal, which complement the company’s existing portfolio of GYN surgical solutions and extend physicians’ choices.

The Omni hysteroscope portfolio offers improved diagnostic and operative versatility through three interchangeable sheaths ranging from 3.7 to 6 millimeters with 0°, or the new 30°, field of view options. The long 200 millimeter working length further supports adapting the procedure to the patient’s anatomy. This system of interchangeable sheaths enables “see and treat” applications by quickly switching from diagnostic to operative hysteroscopy, even in an outpatient environment, with less need for sterilization. The Omni hysteroscope with its premium HD rod lens is therefore designed to enable an optimal hysteroscopic experience.

The addition of the Omni™ Lok cervical seal and the Omni 5 French seal cap to Hologic’s portfolio supports procedural efficiency. The Omni Lok seal is a first-in-its-class product designed to help maintain uterine distention and improve procedural efficiency in the operating room (OR) by minimizing fluid leakage during hysteroscopic procedures by an average of 94%.1,2 It is compatible with MyoSure® and Omni hysteroscopes. The Omni 5 French Seal Cap also can reduce leakage and backsplash by over 75% when using 5 French tools.3

“The option to ‘see and treat’ is becoming more common across Europe. There is an increasing awareness of the benefits of moving these types of procedures to the out-patient environment and this has been further highlighted by the pandemic. Gynecologists need to have access to a wider range of products that enable them to adapt quickly to the requirements of each patient,” said Tanja Brycker, VP Strategic Development BSH & Surgical - International. “Hologic has consulted extensively with our customers, and the latest additions to the Omni suite of hysteroscopic products were developed based on their feedback. This is especially true for the Omni 30° hysteroscope, which clearly demonstrates our continuing commitment to meeting our customers’ needs. We expect Omni 30° will quickly become a device of choice for use in out-patients by gynecologists across EMEA.”

Managing fluid loss is a critical element of hysteroscopies, as less fluid on floors and the operating table can improve physician estimates of fluid loss, as well as reduce cleanup and OR turnover time. This in turn may help physicians schedule more patients, increasing productivity.1,2

Hologic’s full product suite includes the Omni 30° and 0° hysteroscopes, the Omni Lok cervical seal and the Omni 5 French seal. The Omni Suite is designed to enhance utilization of Hologic’s wider GYN surgical portfolio including the MyoSure® tissue removal system and the Fluent® fluid management system.

For more information on these products and Hologic’s full hysteroscopic procedure portfolio, visit Gynsurgicalsolutions.co.uk .

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com .

Hologic, Fluent, MyoSure, NovaSure, Omni and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Important Safety Information

The Omni® 0° and 30° hysteroscopes are intended to provide viewing of the cervical canal and uterine cavity for the purpose of performing diagnostic and operative procedures. The Omni 0° and 30° hysteroscopes are not appropriate for patients who are exhibiting acute pelvic inflammatory disease or exhibit the following conditions: inability to distend uterus, cervical stenosis, cervical/vaginal infection, uterine bleeding or menses, invasive carcinoma of the cervix, recent uterine perforation, medical contraindications, or intolerance to anesthesia.

The Omni® Lok cervical seal is used during a hysteroscopic procedure to minimize liquid distention media leakage from the cervix. The Omni Lok cervical seal should not be used in a patient with a contraindication to hysteroscopy.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com .

SOURCE: Hologic, Inc.


1 Hologic Data on file. VAR-08420. Physician questionnaire after video introduction to device; N=15
2 Hologic Data on file, VER-09159, bench test utilizing a uterine model; N=22
3 Hologic data on file. VER-10319

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release

Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye